- Maxwellia, an Alderley Park, UK-based self-care company, raised £3.2m in funding
- The round led by Praetura Ventures with participation from the Future Fund, Catapult Ventures, Alderley Park Ventures and Biocity along with individual and angel investors
- In conjunction with the funding, Praetura Ventures director Dr Andy Round became a non-executive director
- The company intends to use the funds to scale up the manufacture and rollout of its drugs following MHRA approval, invest in marketing and expand its team
- Maxwellia aims to give people access to the treatments they need by converting prescription-only medicines to versions that can bought in a pharmacy
- It already has three applications under assessment with the MHRA, and is currently awaiting approval of its women’s health product following a public consultation
